{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:53:22Z","timestamp":1762376002417},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030_156829"],"award-info":[{"award-number":["310030_156829"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.nucmedbio.2015.09.003","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T11:24:06Z","timestamp":1442057046000},"page":"81-88","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["5-HT2A receptor SPECT imaging with [ 123 I]R91150 under P-gp inhibition with tariquidar: More is better?"],"prefix":"10.1016","volume":"43","author":[{"given":"Stergios","family":"Tsartsalis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin B.","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinh","family":"Huynh-Gatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Ginovart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelle","family":"Moulin-Sallanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Millet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","article-title":"Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases","volume":"76","author":"Loscher","year":"2005","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1098-2396(200004)36:1<66::AID-SYN7>3.0.CO;2-J","article-title":"Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood\u2013brain barrier","volume":"36","author":"Doze","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0015","doi-asserted-by":"crossref","DOI":"10.2310\/7290.2013.00072","article-title":"Small-animal single-photon emission computed tomographic imaging of the brain serotoninergic systems in wild-type and mdr1a knockout rats","volume":"13","author":"Dumas","year":"2014","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2191-219X-3-24","article-title":"Radiosynthesis and preclinical evaluation of [11C]prucalopride as a potential agonist PET ligand for the 5-HT4 receptor","volume":"3","author":"Buiter","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2191-219X-2-12","article-title":"[11C]Flumazenil brain uptake is influenced by the blood\u2013brain barrier efflux transporter P-glycoprotein","volume":"2","author":"Froklage","year":"2012","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0014-2999(00)00752-4","article-title":"Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats","volume":"407","author":"Passchier","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2013.09.001","article-title":"[(1)(8)F]Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT(2)A receptor densities in the rat brain","volume":"41","author":"Kroll","year":"2014","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00259-008-0968-x","article-title":"Effect of cyclosporin A administration on the biodistribution and multipinhole muSPECT imaging of [123I]R91150 in rodent brain","volume":"36","author":"Blanckaert","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2967\/jnumed.107.047308","article-title":"11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux","volume":"49","author":"Zoghbi","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0050","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.neuroimage.2009.09.048","article-title":"Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar","volume":"49","author":"la Fougere","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0055","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00259-008-0832-z","article-title":"Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies","volume":"35","author":"Lacan","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14737140.7.4.447","article-title":"Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor","volume":"7","author":"Fox","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0065","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/jlcr.2580340902","article-title":"Radiosynthesis of a new radioidinated ligand for serotonin-5Ht2-receptor, a promising tracer for gamma-emission tomography","volume":"34","author":"Mertens","year":"1994","journal-title":"J Labelled Comp Radiopharm"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s002130100761","article-title":"In vivo 5-HT2A receptor blockade by quetiapine: an R91150 single photon emission tomography study","volume":"157","author":"Jones","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002590000392","article-title":"Decreased frontal serotonin 5-HT 2a receptor binding index in deliberate self-harm patients","volume":"28","author":"Audenaert","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0080","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2967\/jnumed.110.081885","article-title":"Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812","volume":"52","author":"Catafau","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0225","doi-asserted-by":"crossref","DOI":"10.2310\/7290.2015.00006","article-title":"In vivo quantification of 5-HT2A brain receptors in Mdr1a KO rats with 123I-R91150 single photon emission computed tomography","volume":"14","author":"Dumas","year":"2015","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0090","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.neuroimage.2008.02.062","article-title":"In vivo quantification of 5-HT1A-[18F]MPPF interactions in rats using the YAP-(S)PET scanner and a beta-microprobe","volume":"41","author":"Millet","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0095","series-title":"The rat brain in stereotaxic coordinates. 2nd ed., Sydney","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jneumeth.2006.01.027","article-title":"Serial microPET measures of the metabolic reaction to a microdialysis probe implant","volume":"155","author":"Schiffer","year":"2006","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0105","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":"Consensus nomenclature for in vivo imaging of reversibly binding radioligands","volume":"27","author":"Innis","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/syn.20348","article-title":"Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(\u2212)-RWAY","volume":"61","author":"Liow","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/clpt.2011.217","article-title":"Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood\u2013brain barrier: a comparison with rat data","volume":"91","author":"Bauer","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0120","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1088\/0031-9155\/50\/22\/R01","article-title":"Small animal SPECT and its place in the matrix of molecular imaging technologies","volume":"50","author":"Meikle","year":"2005","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0125","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2967\/jnumed.108.051235","article-title":"Tariquidar-induced P-glycoprotein inhibition at the rat blood\u2013brain barrier studied with (R)-11C-verapamil and PET","volume":"49","author":"Bankstahl","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0130","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjp.0701979","article-title":"Complete in vivo reversal of P-glycoprotein pump function in the blood\u2013brain barrier visualized with positron emission tomography","volume":"124","author":"Hendrikse","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11307-005-0951-x","article-title":"Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain","volume":"7","author":"Elsinga","year":"2005","journal-title":"Mol Imaging Biol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2015.09.003_bb0140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/jcbfm.2015.19","article-title":"Approaching complete inhibition of P-glycoprotein at the human blood\u2013brain barrier: an (R)-[C]verapamil PET study","volume":"35","author":"Bauer","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0145","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2967\/jnumed.109.063289","article-title":"A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood\u2013brain barrier with (R)-11C-verapamil and PET","volume":"50","author":"Wagner","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0150","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2967\/jnumed.109.070151","article-title":"P-glycoprotein function at the blood\u2013brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide","volume":"51","author":"Kreisl","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.nucmedbio.2012.09.010","article-title":"Radiolabelling and PET brain imaging of the alpha(1)-adrenoceptor antagonist Lu AE43936","volume":"40","author":"Risgaard","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0160","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-009-1332-5","article-title":"Dose\u2013response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood\u2013brain barrier using (R)-[(11)C]verapamil PET","volume":"37","author":"Kuntner","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0165","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.nucmedbio.2013.05.012","article-title":"(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood\u2013brain barrier, and not by MRP1 and BCRP","volume":"40","author":"Romermann","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.18433\/J3RC77","article-title":"Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy","volume":"12","author":"Bansal","year":"2009","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \"specific\" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(02)01453-2","article-title":"Differential expression of multidrug resistance genes in naive rat brain","volume":"339","author":"Kwan","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0185","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/mi.9.3.7","article-title":"Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice","volume":"9","author":"Lagas","year":"2009","journal-title":"Mol Interv"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/2191-219X-2-58","article-title":"Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood\u2013brain barriers studied with (R)-[11C]verapamil positron emission tomography","volume":"2","author":"Mullauer","year":"2012","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0195","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.nucmedbio.2013.11.008","article-title":"Quantification of GABAA receptors in the rat brain with [(123)I]Iomazenil SPECT from factor analysis-denoised images","volume":"41","author":"Tsartsalis","year":"2014","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0200","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00259-014-2976-3","article-title":"[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents","volume":"42","author":"Haeusler","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0205","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00259-014-2936-y","article-title":"Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging","volume":"42","author":"Becker","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0210","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2967\/jnumed.113.125351","article-title":"PET brain imaging of neuropeptide Y2 receptors using N-11C-methyl-JNJ-31020028 in pigs","volume":"55","author":"Winterdahl","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb0215","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/jcbfm.2009.265","article-title":"Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood\u2013brain barrier","volume":"30","author":"Bauer","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb9000","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.nucmedbio.2011.10.017","article-title":"Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil","volume":"39","author":"Verbeek","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb8000","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13550-015-0088-0","article-title":"A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice","volume":"5","author":"Slobbe","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2015.09.003_bb7000","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.nucmedbio.2012.08.005","article-title":"Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113","volume":"39","author":"Mairinger","year":"2012","journal-title":"Nucl Med Biol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805115001626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805115001626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T08:29:17Z","timestamp":1567153757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805115001626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0969805115001626"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.09.003","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-HT2A receptor SPECT imaging with [123I]R91150 under P-gp inhibition with tariquidar: More is better?","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}